AI-enhanced oncology MDT 2.0: from multi-modal data synergy to value-based care reconstruction - a systematic review of clinical efficacy and socioeconomic benefits - Report - MDSpire
Advertisement
AI-enhanced oncology MDT 2.0: from multi-modal data synergy to value-based care reconstruction - a systematic review of clinical efficacy and socioeconomic benefits
Clinical Report: AI-Driven Oncology Multidisciplinary Teams 2.0
Overview
This systematic review evaluates the clinical efficacy and socioeconomic implications of integrating AI into oncology multidisciplinary team (MDT) decision-making. Key findings indicate AI systems achieve concordance rates of 62-76% with human tumor boards, particularly in guideline-driven decisions, while also highlighting limitations in complex cases.
Background
Multidisciplinary team meetings are essential for treatment planning in oncology, yet they face challenges such as variability in decision-making and unequal access to expertise. The integration of AI, particularly large language models, presents an opportunity to enhance decision-making processes and improve patient outcomes. Understanding the clinical effectiveness and economic impact of AI in this context is crucial for advancing oncology care.
Data Highlights
No specific numerical data or trial data presented in the article.
Key Findings
AI systems achieve concordance rates of 62-76% with human tumor boards across multiple cancer types.
AI demonstrates strengths in standardizing guideline-adherent recommendations and supporting molecular target identification.
Limitations exist in AI's ability to handle complex, individualized clinical cases.
AI integration has potential socioeconomic benefits, including reduced MDT preparation time and improved access to subspecialty expertise.
Rigorous cost-effectiveness evidence for AI in oncology remains limited.
Clinical Implications
The findings suggest that AI can augment human decision-making in oncology MDTs, particularly in standardizing care and improving access. However, clinicians should remain aware of AI's limitations in nuanced clinical judgment.
Conclusion
AI-Enhanced Oncology MDT 2.0 represents a strategic augmentation of human judgment rather than a replacement, highlighting the need for careful integration into clinical workflows.
